Sirona Biochem Corp.

SBM

CA82967M1005

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 20:59:59 04/07/2024 BST			5-day change	1st Jan Change
0.06 ^CAD	+20.00%		+20.00%	-50.00%

06-20	Sirona Biochem Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI
05-07	Sirona Biochem Engages Stonegate Healthcare Partners	CI

Sirona Biochem Shareholder Q&A Webinar

January 16, 2023 at 03:05 pm

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ('Sirona') is pleased to announce that we will host a webinar on January 17th 2023 at 10:00 AM - 11:00 AM PST.

Contact:

Tel: 604.641.4466

Email: info@sironabiochem.com

Latest news about Sirona Biochem Corp.

Sirona Biochem Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	06-20	CI
Sirona Biochem Engages Stonegate Healthcare Partners	05-07	CI
Sirona Biochem Provides Update on Anti-Aging Product	04-08	MT
Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding	04-03	CI
Sirona Biochem Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	04-01	CI
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations	03-13	MT
Sirona Biochem Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	02-28	CI
Sirona Biochem Corp. Announces Loan in the Aggregate Principal Amount of Up to $1,000,000	01-29	CI
Sirona Biochem Initiated Private Placement	01-29	MT
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding	01-28	CI
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding	01-25	CI
Sirona Biochem Corrects Earlier Statement	01-24	MT
Sirona Biochem Provides Corporate Update	01-24	MT
Sirona Biochem Launches Cosmetics Subsidiary	01-15	MT
Sirona Biochem Corp. Introduces A Wholly-Owned Subsidiary Sirona Laboratories	01-15	CI
Sirona Biochem Initiates GlycoProteMim Trademark for Anti-Aging Molecule TFC-1326	12-11	MT
Sirona Biochem Corp. Initiates GlycoProteMim?? Trademark for Anti-Aging Molecule TFC-1326	12-11	CI
Sirona Biochem Corp. Announces the Results of Its Research Collaboration with the International Centre for Genetic Engineering and Biotechnology in Advancing Sirona's Antiviral Compound Library	11-29	CI
Sirona Biochem Announced Payment of Convertible Debenture Interests in Shares	20/10/23	MT
Sirona Biochem Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	29/09/23	CI
Sirona Biochem Provides Strategic Review Update	13/07/23	MT
Sirona Biochem Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	29/06/23	CI
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEB	28/06/23	CI
Sirona Biochem to Present Anti-Aging Technology at BIO 2023 Conference in Boston	03/05/23	MT
Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326	25/04/23	CI

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChemâs proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).

Sector

Biotechnology & Medical Research

Calendar

25/09/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SIRONA BIOCHEM CORP.	-50.00%	11.32M
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+42.66%	40.03B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research

Sirona Biochem Corp.

Equities

SBM

CA82967M1005

Biotechnology & Medical Research

Sirona Biochem Shareholder Q&A Webinar

Latest news about Sirona Biochem Corp.

Chart Sirona Biochem Corp.

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research